These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30146169)

  • 1. Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARγ; a Model for Ligand-Dependent Antagonism.
    Zheng J; Corzo C; Chang MR; Shang J; Lam VQ; Brust R; Blayo AL; Bruning JB; Kamenecka TM; Kojetin DJ; Griffin PR
    Structure; 2018 Nov; 26(11):1431-1439.e6. PubMed ID: 30146169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
    Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological repression of PPARγ promotes osteogenesis.
    Marciano DP; Kuruvilla DS; Boregowda SV; Asteian A; Hughes TS; Garcia-Ordonez R; Corzo CA; Khan TM; Novick SJ; Park H; Kojetin DJ; Phinney DG; Bruning JB; Kamenecka TM; Griffin PR
    Nat Commun; 2015 Jun; 6():7443. PubMed ID: 26068133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A molecular switch regulating transcriptional repression and activation of PPARγ.
    Shang J; Mosure SA; Zheng J; Brust R; Bass J; Nichols A; Solt LA; Griffin PR; Kojetin DJ
    Nat Commun; 2020 Feb; 11(1):956. PubMed ID: 32075969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent Modifier Discovery Using Hydrogen/Deuterium Exchange-Mass Spectrometry.
    Kojima H; Yanagi R; Higuchi E; Yoshizawa M; Shimodaira T; Kumagai M; Kyoya T; Sekine M; Egawa D; Ohashi N; Ishida H; Yamamoto K; Itoh T
    J Med Chem; 2023 Apr; 66(7):4827-4839. PubMed ID: 36994595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
    Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
    Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.
    Hughes TS; Chalmers MJ; Novick S; Kuruvilla DS; Chang MR; Kamenecka TM; Rance M; Johnson BA; Burris TP; Griffin PR; Kojetin DJ
    Structure; 2012 Jan; 20(1):139-50. PubMed ID: 22244763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of magnolol targeting both RXRα and PPARγ.
    Zhang H; Xu X; Chen L; Chen J; Hu L; Jiang H; Shen X
    PLoS One; 2011; 6(11):e28253. PubMed ID: 22140563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linked magnolol dimer as a selective PPARγ agonist - Structure-based rational design, synthesis, and bioactivity evaluation.
    Dreier D; Latkolik S; Rycek L; Schnürch M; Dymáková A; Atanasov AG; Ladurner A; Heiss EH; Stuppner H; Schuster D; Mihovilovic MD; Dirsch VM
    Sci Rep; 2017 Oct; 7(1):13002. PubMed ID: 29057944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.
    Mottin M; Souza PC; Ricci CG; Skaf MS
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.
    Brust R; Shang J; Fuhrmann J; Mosure SA; Bass J; Cano A; Heidari Z; Chrisman IM; Nemetchek MD; Blayo AL; Griffin PR; Kamenecka TM; Hughes TS; Kojetin DJ
    Nat Commun; 2018 Nov; 9(1):4687. PubMed ID: 30409975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs.
    Puhl AC; Milton FA; Cvoro A; Sieglaff DH; Campos JC; Bernardes A; Filgueira CS; Lindemann JL; Deng T; Neves FA; Polikarpov I; Webb P
    Nucl Recept Signal; 2015; 13():e004. PubMed ID: 26445566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ.
    Heidari Z; Chrisman IM; Nemetchek MD; Novick SJ; Blayo AL; Patton T; Mendes DE; Diaz P; Kamenecka TM; Griffin PR; Hughes TS
    Nat Commun; 2019 Dec; 10(1):5825. PubMed ID: 31862968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
    Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
    Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
    Miyamae Y
    Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
    Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Regulation of Coregulator/Nuclear Receptor Interaction by Ligand and DNA.
    de Vera IMS; Zheng J; Novick S; Shang J; Hughes TS; Brust R; Munoz-Tello P; Gardner WJ; Marciano DP; Kong X; Griffin PR; Kojetin DJ
    Structure; 2017 Oct; 25(10):1506-1518.e4. PubMed ID: 28890360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.